Cargando…

[(225)Ac]Ac- and [(111)In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

BACKGROUND: Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain. Radioimmunotherapy (RIT) with trastuzumab labeled with α-particle emitting, (225)Ac may overc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondo, Misaki, Cai, Zhongli, Chan, Conrad, Forkan, Nubaira, Reilly, Raymond M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522541/ https://www.ncbi.nlm.nih.gov/pubmed/37750937 http://dx.doi.org/10.1186/s41181-023-00208-0

Ejemplares similares

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

Preclinical evaluation of an (111)In/(225)Ac theranostic targeting transformed MUC1 for triple negative breast cancer
por: Kelly, Vanessa J, et al.
Publicado: (2020)

Dose predictions for [(177)Lu]Lu-DOTA-panitumumab F(ab′)(2) in NRG mice with HNSCC patient-derived tumour xenografts based on [(64)Cu]Cu-DOTA-panitumumab F(ab′)(2) – implications for a PET theranostic strategy
por: Ku, Anthony, et al.
Publicado: (2021)

Evaluation of the pharmacokinetics, dosimetry, and therapeutic efficacy for the α-particle-emitting transarterial radioembolization (αTARE) agent [(225)Ac]Ac-DOTA-TDA-Lipiodol(®) against hepatic tumors
por: Josefsson, Anders, et al.
Publicado: (2023)

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

Development of [(225)Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration
por: Hull, Ashleigh, et al.
Publicado: (2023)

Initial Findings on the Use of [(225)Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors
por: Demirci, Emre, et al.
Publicado: (2023)

Alpha radioimmunotherapy using (225)Ac-proteus-DOTA for solid tumors - safety at curative doses
por: Cheal, Sarah M., et al.
Publicado: (2020)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022)

Image-based dosimetry for (225)Ac-PSMA-I&T therapy using quantitative SPECT
por: Gosewisch, A., et al.
Publicado: (2020)

Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization
por: Pandya, Darpan N., et al.
Publicado: (2016)

Towards Alpha Dosimetry with Laser Ionized and Mass Separated 225Ac: Setup Development and Source Characterization
por: Van den Bergh, Viktor
Publicado: (2022)

A GATE simulation study for dosimetry in cancer cell and micrometastasis from the (225)Ac decay chain
por: Koniar, Helena, et al.
Publicado: (2023)

A comparison of (111)In- or (64)Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT
por: Chan, Conrad, et al.
Publicado: (2011)

Cure of Disseminated Human Lymphoma with [(225)Ac]Ac-Ofatumumab in a Preclinical Model
por: Longtine, Mark S., et al.
Publicado: (2023)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
por: Delker, Astrid, et al.
Publicado: (2023)

Evaluation of (134)Ce/(134)La as a PET Imaging Theranostic Pair for (225)Ac α-Radiotherapeutics
por: Bobba, Kondapa Naidu, et al.
Publicado: (2023)

Resonant laser ionization and mass separation of $^{225}$Ac
por: Johnson, Jake D, et al.
Publicado: (2023)

Comparison of the biodistribution of $^{225}$Ac and radiolanthanides as citrate complexes
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1990)

The application of poorly crystalline silicotitanate in production of (225)Ac
por: Fitzsimmons, Jonathan, et al.
Publicado: (2019)

Development of (225)Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
por: Robertson, Andrew Kyle Henderson, et al.
Publicado: (2018)

Resonant laser ionization and mass separation of (225)Ac
por: Johnson, Jake D., et al.
Publicado: (2023)

Estimating (225)Ac yield in thorium metal targets
por: Rahmani, M., et al.
Publicado: (2023)

Relative Efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
por: Lee, Hwan
Publicado: (2022)

First In Vivo and Phantom Imaging of Cyclotron-Produced (133)La as a Theranostic Radionuclide for (225)Ac and (135)La
por: Nelson, Bryce J.B., et al.
Publicado: (2022)

Ac-EAZY! Towards GMP-Compliant Module Syntheses of (225)Ac-Labeled Peptides for Clinical Application
por: Pretze, Marc, et al.
Publicado: (2021)

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023)

Towards reliable production of 225Ac for medical applications: Systematic analysis of the production of Fr, Ra and Ac beams.
por: Dockx, Kristof, et al.
Publicado: (2017)

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, (111)In or β-particle emitting, (177)Lu
por: Aghevlian, Sadaf, et al.
Publicado: (2020)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

New measurement of exotic decay of $^{225}$Ac by $^{14}$C emission
por: Guglielmetti, A, et al.
Publicado: (2001)

Cyclotron production of (225)Ac from an electroplated (226)Ra target
por: Nagatsu, Kotaro, et al.
Publicado: (2021)

α-Zirconium(IV) Phosphate: Static Study of (225)Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using (nat)Eu as a Model System for (225)Ac
por: Ondrák, Lukáš, et al.
Publicado: (2023)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

Solid-phase extraction of $^{225}$Ac using ion-imprinted resin and $^{243}$Am as a radioactive tracer for internal dosimetry and incorporation measurements
por: Cusnir, Ruslan, et al.
Publicado: (2022)

Development of (225)Ac Production from Low Isotopic Dilution (229)Th
por: Camacaro, Jose F., et al.
Publicado: (2023)

Signaling Network Response to α-Particle–Targeted Therapy with the (225)Ac-Labeled Minigastrin Analog (225)Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors
por: Qin, Yun, et al.
Publicado: (2023)

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with (225)Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer
por: Cędrowska, Edyta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u2lbbcrlmlknv2gnrnkq50cr9j